Ryan Fukushima Sells 20,000 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the completion of the transaction, the chief operating officer now directly owns 982,442 shares of the company’s stock, valued at approximately $38,914,527.62. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total value of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The shares were sold at an average price of $42.51, for a total value of $5,101,200.00.

Tempus AI Stock Down 3.6 %

NASDAQ:TEM traded down $1.39 during trading hours on Wednesday, reaching $37.49. The company’s stock had a trading volume of 2,974,666 shares, compared to its average volume of 3,782,261. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The firm has a 50-day simple moving average of $48.75 and a 200-day simple moving average of $47.03. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wolfe Research began coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Loop Capital boosted their price target on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and lifted their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Piper Sandler reaffirmed a “neutral” rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Finally, Bank of America boosted their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Pier Capital LLC purchased a new position in shares of Tempus AI in the second quarter worth $2,301,000. Federated Hermes Inc. bought a new stake in Tempus AI in the 2nd quarter worth $19,886,000. Revolution Growth Management Company Inc. purchased a new position in shares of Tempus AI in the second quarter valued at about $128,133,000. Allen Operations LLC bought a new position in shares of Tempus AI during the second quarter valued at about $3,831,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Tempus AI during the second quarter worth about $634,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.